As of now, there are no CSF1R inhibitors that have received full approval from regulatory bodies like the FDA for cancer treatment. However, several candidates are in various stages of clinical trials. For instance, drugs such as pexidartinib have shown promise and are being investigated for their potential use in cancer therapy.
